Challenges in proliferative vitreoretinopathy: is biological therapy a solution?

References

• Charteris DG. Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment. Eye (Lond). 2020;34(2):241–245. doi: 10.1038/s41433-019-0699-1
   PubMed Web of Science ®Google Scholar
• Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21(1):127–144. doi: 10.1016/S1350-9462(01)00023-4
   PubMed Web of Science ®Google Scholar
• Lai FH, Lo EC, Chan VC, et al. Combined pars plana vitrectomy-scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy. Int Ophthalmol. 2016;36(2):217–224. doi: 10.1007/s10792-015-0104-4
   PubMed Web of Science ®Google Scholar
• Anguita R, Roth J, Makuloluwa A, et al. Late presentation of retinal detachment: clinical features and surgical outcomes. Retina. 2021;41(9):1833–1838. doi: 10.1097/IAE.0000000000003131
   PubMed Web of Science ®Google Scholar
• Banerjee PJ, Quartilho A, Bunce C, et al. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmol. 2017;124(6):757–767. doi: 10.1016/j.ophtha.2017.01.021
   PubMed Web of Science ®Google Scholar
• Wickham L, Ho-Yen GO, Bunce C, et al. Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes. Br J Ophthalmol. 2011;95(9):1234–1238. doi: 10.1136/bjo.2010.190306
   PubMed Web of Science ®Google Scholar
• Kon CH, Asaria RH, Occleston NL, et al. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84(5):506–511. doi: 10.1136/bjo.84.5.506
   PubMed Web of Science ®Google Scholar
• Eliott D, Stryjewski TP, Andreoli MT, et al. Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment. Retina. 2017;37(7):1229–1235. doi: 10.1097/IAE.0000000000001361
   PubMed Web of Science ®Google Scholar
• Patel NN, Bunce C, Asaria RH, et al. Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina. 2004;24(6):883–887. doi: 10.1097/00006982-200412000-00007
   PubMed Web of Science ®Google Scholar
• Pastor JC, Rojas J, Pastor-Idoate S, et al. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125–155. doi: 10.1016/j.preteyeres.2015.07.005
   PubMed Web of Science ®Google Scholar
• Idrees S, Sridhar J, Kuriyan AE. Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin. 2019;59(1):221–240. doi: 10.1097/IIO.0000000000000258
   PubMedGoogle Scholar
• Chandler DB, Hida T, Sheta S, et al. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 1987;225(4):259–265. doi: 10.1007/BF02150144
   PubMed Web of Science ®Google Scholar
• Munir WM, Pulido JS, Sharma MC, et al. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005;40(5):598–604. doi: 10.1016/S0008-4182(05)80052-3
   PubMed Web of Science ®Google Scholar
• Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23(4):739–755. doi: 10.1016/S0889-857X(05)70358-6
   PubMed Web of Science ®Google Scholar
• Olsen TW, Asheim CG, Salomao DR, et al. Aerosolized, gas-phase, intravitreal methotrexate reduces proliferative vitreoretinopathy in a randomized trial in a porcine model. Ophthalmol Sci. 2023;3(3):100296. doi: 10.1016/j.xops.2023.100296
   PubMedGoogle Scholar
• Jahangir S, Jahangir T, Ali MH, et al. Use of intravitreal methotrexate Infusion in complicated retinal detachment for prevention of proliferative vitreoretinopathy in a pilot study. Cureus. 2021;13(8):e17439. doi: 10.7759/cureus.17439
   PubMed Web of Science ®Google Scholar
• McAllister MA, Moore SM, Bullock B, et al. Intraocular methotrexate for the treatment and prevention of proliferative vitreoretinopathy: a review. J Vitreoretin Dis. 2023;7(2):144–153. doi: 10.1177/24741264221135799
   PubMedGoogle Scholar
• Wiedemann P. What can we learn from negative results in clinical trials for proliferative vitreoretinopathy? Int J Ophthalmol. 2022;15(9):1413–1415. doi: 10.18240/ijo.2022.09.01
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi: 10.1038/nrc1074
   PubMed Web of Science ®Google Scholar
• Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2017;18(16):1765–1780. doi: 10.1080/14656566.2017.1391216
   PubMed Web of Science ®Google Scholar
• Chen EP, Steinhorst UH, Samsa GP, et al. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33(7):2160–2164.
   PubMed Web of Science ®Google Scholar
• Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmol. 2001;108(7):1179–1183. doi: 10.1016/S0161-6420(01)00589-9
   PubMed Web of Science ®Google Scholar
• Azzolini C, Pagani IS, Pirrone C, et al. Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy. Mediators Inflamm. 2013;2013:857380. doi: 10.1155/2013/857380
   PubMed Web of Science ®Google Scholar
• Pennock S, Kim D, Mukai S, et al. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol. 2013;182(5):1659–1670. doi: 10.1016/j.ajpath.2013.01.052
   PubMed Web of Science ®Google Scholar
• Hsu J, Khan MA, Shieh WS, et al. Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment. Am J Ophthalmol. 2016;161:65-70 e1–2. doi: 10.1016/j.ajo.2015.09.029
   Web of Science ®Google Scholar
• Zhao XY, Xia S, Wang EQ, et al. EFFICACY of INTRAVITREAL INJECTION of BEVACIZUMAB in VITRECTOMY for PATIENTS with PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: a meta-analysis of prospective studies. Retina. 2018;38(3):462–470. doi: 10.1097/IAE.0000000000001584
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakao S, Arima M, et al. Rho-kinase/ROCK as a potential drug target for vitreoretinal diseases. J Ophthalmol. 2017;2017:8543592. doi: 10.1155/2017/8543592
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Intravitreal infliximab for proliferative vitreoretinopathy (FIXER). 2023. https://clinicaltrials.gov/ct2/show/NCT04891991
   Google Scholar
• ClinicalTrial.gov. Adrenocorticotropic Hormone (ACTH) for post-op inflammation in proliferative vitreoretinopathy (PVR). 2023. https://clinicaltrials.gov/ct2/show/NCT03727776?cond=Proliferative+Vitreoretinopathy&draw=2&rank=4
   Google Scholar
• Di Lauro S, Kadhim MR, Charteris DG, et al. Classifications for proliferative vitreoretinopathy (PVR): an analysis of their use in publications over the last 15 years. J Ophthalmol. 2016;2016:7807596. doi: 10.1155/2016/7807596
   PubMed Web of Science ®Google Scholar